Regenerative Medical Technology (RMTG) Non Operating Interest Expenses (2018 - 2026)

Regenerative Medical Technology has reported Non Operating Interest Expenses for 9 years, with the latest figure at $2.2 million in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses rose 111.66% year-over-year to $2.2 million in Q2 2026; TTM through Jun 2026 was $9.9 million, a 155.98% increase from a year earlier, with the FY2025 full-year figure at $7.4 million, up 32.02% from the prior year.
• Non Operating Interest Expenses was $2.2 million for Q2 2026 at Regenerative Medical Technology, up from $2.2 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $3.5 million in Q3 2025, with the low at $895850.0 in Q1 2025.
• Average Non Operating Interest Expenses over 5 years is $1.6 million, with a median of $1.6 million recorded in 2023.
• The largest YoY upside for Non Operating Interest Expenses was 285.5% in 2025 against a maximum downside of 51.69% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at $1.2 million in 2022, then surged by 38.03% to $1.6 million in 2023, then plunged by 37.56% to $1.0 million in 2024, then soared by 96.88% to $2.0 million in 2025, then gained by 11.27% to $2.2 million in 2026.
• The last three Non Operating Interest Expenses figures came in at $2.2 million (Q2 2026), $2.2 million (Q1 2026), and $2.0 million (Q4 2025), per Business Quant data.